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Proteomic characterization of the cytotoxic mechanism
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There has been increasing interest in the potential applications of gold (III) complexes as antic-
ancer drugs with higher cytotoxicity and fewer side effects than existing metal anticancer drugs.
Our previous findings demonstrated that gold (III) porphyrin 1a preferentially induced apoptosis
in a cancer cell line (SUNE1). In this study, we identified differentially expressed proteins related
to the drug’s cytotoxic action by comparing the protein alterations induced by gold (III) por-
phyrin 1a and cisplatin treatments. Several clusters of altered proteins were identified, including
cellular structure and stress-related chaperone proteins, proteins involved in reactive oxygen
species and enzyme proteins, translation factors, proteins that mediate cell proliferation or dif-
ferentiation, and proteins participating in the internal degradation systems. Our results indi-
cated that multiple factors leading to apoptosis were involved in drug cytotoxicity in SUNE1 cells.
The balance between pro-apoptotic and anti-apoptotic signals determined the final fate of cancer
cells.
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1 Introduction
In the past few decades considerable effort has been devoted
to the search for new chemotherapeutic agents with pref-
erential anticancer activity. However, although there have
been important developments in the field of anticancer che-
motherapy, no breakthrough has been achieved in the search
for better anticancer agents since the introduction of cis--
diamminedichloro-platinum (II) (cisplatin) into clinical use
[1, 2]. In recent years research has increasingly focused on the
potential of gold (III) complexes as anticancer drug candi-
dates, because gold (III) possesses the same isoelectronic
configuration (d8) and structural (square planar) character-
istics as platinum (II) [3–5]. Our laboratories have been
attempting to develop gold (III) meso-tetraarylporphyrins as
potential chemotherapeutic leads [6]. We have previously
reported that one of these complexes, gold (III) meso-tetra-
arylporphyrin 1a [gold (III) porphyrin 1a] (Fig. 1A), is a
promising new chemotherapeutic lead ([6], and to be pub-
lished). In this study we used a proteomic approach to further
investigate the action mechanism of gold (III) porphyrin 1a
in suppressing cancer cell growth. Cisplatin was chosen as a
control drug because it is one of the most widely used metal-
containing anticancer drugs, and the action mechanism of
cisplatin-induced apoptosis has been well documented [7, 8].
In addition, the drug resistance and side effects of cisplatin
Correspondence: Professor Jen-Fu Chiu, Department of Anat-
omy, Department of Chemistry, University of Hong Kong, Pok-
fulam, Hong Kong SAR, China
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Abbreviations: CacyBP, calcyclin binding protein; Cisplatin, cis-
diamminedichloro-platinum (II); CLIC 1, chloride intracellular
channel protein 1; DAPI, 4, 6-diamidino-2-phenylindole; GDI, rho
GDP dissociation inhibitor alpha; IC50, half-maximal inhibitory
concentration;mtSSB, mitochondrial single-stranded DNA bind-
ing protein;NBB, naphthol blue black;Op18, oncoprotein 18; PDI,
protein disulfide isomerase 1; ROS, reactive oxygen species;
VDAC1, voltage-dependent anion channel 1
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Figure 1. Chemical structures of gold (III) porphyrin 1a (A) and
cisplatin (B).
still pose major problems for its clinical use [9, 10]. There is
an urgent need for the development of new anticancer drug
candidates to replace cisplatin. This is particularly important
for patients who respond poorly to cisplatin treatment.
Previous studies have indicated that apoptosis induced
by interaction with DNA is an important mechanism by
which chemotherapeutic agents kill susceptible cells [11]. For
example, cisplatin causes apoptosis through cross-linking
with DNA [7, 8], and bleomycin induces apoptosis by DNA
fragmentation [12, 13]. Apoptosis, or programmed cell death,
is a type of cell death involving characteristic morphological
and biochemical changes. This process is achieved via the
aggregation and multimerization of the upstream molecules
of the death effector that activate sequential pathways. These
pathways play pivotal roles in the regulation of cellular
physiological and pathological conditions in response to
chemotherapeutic cytotoxicity [14, 15]. Recent studies have
made important progress in identifying key molecular com-
ponents of this intracellular suicide program [16, 17]. As
proteins are the key mediators of cellular activities, the
alteration of cellular protein profiles after treatment with
chemotherapeutic agents could provide valuable information
to improve our understanding of the cytotoxic mechanism of
anticancer agents [18].
The relatively recent discipline of proteomics involves
the study and characterization of the protein products of the
genome, known as the proteome [19]. The scope of prote-
omics also includes the analysis of protein cellular activities
and functions, including the characterization of the flow of
information within the cell. Some of this information is
provided by protein networks organized in discrete signal
transduction pathways, which control cell apoptosis [20].
Proteomic profiling therefore offers a good chance of iden-
tifying the proteins that mediate the apoptosis pathways
involved when cells are treated with chemotherapeutic
agents [21]. By comparing the protein profile of SUNE1
cancer cells treated by gold (III) porphyrin 1a (Fig. 1A) and
cisplatin (Fig. 1B), differentially expressed proteins were
identified by PMF, and further confirmed by Western blot
analysis. Detailed functional analyses of these altered pro-
teins have elucidated the action mechanisms of gold (III)
porphyrin 1a and confirmed its potential as an anticancer
drug.
2 Materials and methods
2.1 Materials and reagents
Gold (III) porphyrin 1a was synthesized and purified by a
method described previously [6]. Cisplatin was purchased
from Sigma-Aldrich Chemical Co. All other chemicals,
except where specifically noted, were purchased from Sigma-
Aldrich Chemical Co. and Amersham Biosciences (Uppsala,
Sweden). Gold (III) porphyrin 1a and cisplatin were dis-
solved in DMSO at concentrations of 1mM and 30mM,
respectively, and kept as stock solutions.
2.2 Cell lines and cell culture
The SUNE1 cell line, a human nasopharyngeal carcinoma
(NPC) cell line derived from poorly differentiated NPC in
Chinese patients [22], and the NP 69 cell line, the normal
nasopharyngeal cell line, were used in this experiment. Both
cell lines were generously provided by Prof. S. W. Tsao
(Department of Anatomy, The University of Hong Kong).
The SUNE1 cell line was cultured in RPMI 1640 medium
with 2.0 g/L sodium bicarbonate plus 10% fetal bovine
serum (JRH Bioscience, Lenexa, KS), 2mmol/L l-glutamine,
100 U/mL penicillin, and 100 mg/mL streptomycin (Gibco-
BRL, Grand Isle, NY, USA). The NP 69 cell line was cultured
in Keratinocyte-SFM (GIBCO) medium plus supplements
for Keratinocyte-SFM (GIBCO). Both cell lines were main-
tained in a humidified incubator with an atmosphere of 95%
air and 5% CO2 at 377C.
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2.3 Cytotoxicity assays
The cytotoxicity of gold (III) porphyrin 1a was determined by
Naphthol Blue Black (NBB) staining assay, according to a
method previously reported [23]. The NP 69 cells were
changed to RPMI 1640 medium the day before the assay to
minimize the effects of different contents in the media on
the cytotoxicity of the analyzed drugs. Both the SUNE1 cells
and the NP 69 cells were plated in 96-well plates at 26104/
well in complete media and incubated overnight. The media
were then changed and the cells were grown in media con-
taining various amounts of gold (III) porphyrin 1a and cis-
platin respectively for 24 h. At the end of the experiment, the
media were removed and the cells were stained by NBB
staining assay [23] andmeasured at 595 nm using aModel E1
310 Autoplate reader (Bio-Tek Instruments, Winooski, VT).
2.4 Confocal imaging of morphological changes
To detect morphological changes in the apoptotic process,
nuclear staining was performed by staining with 1 mg/mL 4,
6-diamidino-2-phenylindole (DAPI) [24], and cells were ana-
lyzed with a fluorescence microscope (Olympus IX71 CTS
Chinetek Scientific Microscope).
2.5 Flow cytometric analysis of cell cycle
Gold (III) porphyrin 1a-induced apoptosis was determined
with flow cytometry according to the method previously
described [23]. Cells were cultivated for 24h before either left
untreated or treatedwith 1 mM gold (III) porphyrin 1a or 30 mM
cisplatin for 24h, respectively. This dose was about the IC50
value (half-maximal inhibitory concentration) of eachagent.At
the end of each experiment, cells were harvested, resuspended
in PBS solution, stained by propidium iodide (PI), and ana-
lyzed with a FACStar Plus flow cytometer. For each sample
16106 cells were analyzed, providing a solid statistical basis
for the determination of the percentage of apoptotic cells in
each treatment using the Lysis II software program.
2.6 2-DE
2-DE was carried out with Amersham Biosystems Ettan
IPGphor IEF System and Ettan Daltsix Tank (18-cm)
units, in accordance with a protocol previously described
[25]. Protein samples (150 mg) were extracted from cells
treated with 1 mM gold (III) porphyrin 1a or 30 mM cisplatin,
and untreated cells were used as control. Triplicate electro-
phoreses were performed to ensure reproducibility. All gels
were visualized by silver staining [25].
2.7 Image analysis and MS PMF
Image acquisition and analysis were performed with an
Image Scanner (Amersham) and Image Master 2D Elite
software (Amersham) [25]. Comparisons were made between
gel images of protein profiles obtained from cells treated
with gold (III) porphyrin 1a or cisplatin and images from
untreated cells. Altered protein spots that changed con-
sistently and significantly (greater than twofold difference)
were selected for analysis with MALDI-TOF MS. These pro-
tein spots were cut out in small pieces and subjected to in-gel
tryptic digestion overnight [25]. Peptide mass spectra were
recorded and previously described parameters for spectral
acquisition were used [25]. Protein identification with
25 ppm or lower mass error and MOWSE scores over 300
were obtained in most analyses during database matching
using MS-Fit (http://prospector.ucsf.edu/). Duplicate or trip-
licate runs were made to ensure the accuracy of analyses.
2.8 Western blot analysis
Cells were lysed and protein extraction was used for Western
blot analysis [23]. The samples were separated on 12% SDS
gel and electrophoretically transferred to PVDF membrane
(Amersham, Buckinghamshire, UK). The membranes were
blotted with 5% skim milk, washed, and probed with pri-
mary antibodies against cyclophilin A (CypA), oncoprotein
18 (Op18), protein disulfide isomerase 1 (PDI), rho GDP
dissociation inhibitor alpha (GDI), and stratifin (Santa Cruz,
CA, USA), respectively. b-Actin (Santa Cruz) was used as an
internal control for protein loading. The membranes were
then washed, incubated with corresponding secondary anti-
bodies, and visualized using an enhanced chemilumines-
cence (ECL) kit (Amersham), in accordance with the manu-
facturer’s recommendations.
3 Results
3.1 Cancer cells are more sensitive to gold (III)
porphyrin 1a than normal cells
According to the results of the NBB staining assay (Fig. 2),
the IC50 of gold (III) porphyrin 1a for NP 69 and SUNE1 cells
were 5.5 mM and 1.5 mM, respectively, and the IC50 of cisplatin
for NP 69 and SUNE1 cells were 47 mM and 3900 mM,
respectively. In other words, gold (III) porphyrin 1a was
around 4 times more toxic to tumor (SUNE1) cells than to
normal (NP 69) cells, while cisplatin was over 82 times more
toxic to SUNE1 cells than to NP 69 cells.
3.2 Gold (III) porphyrin 1a induces apoptosis in
SUNE1 cells
It has been reported that cancer cells undergo apoptosis
under cisplatin treatment [26–29]. In this study, nuclear
morphologies were obtained in normal and cancer cells after
treatment with gold (III) porphyrin 1a or cisplatin for 24 h,
assessed by DAPI staining (Fig. 3A). Apoptotic morphologi-
cal changes were observed in gold (III) porphyrin 1a-treated
cancer cells, but no such changes were observed in normal
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Figure 2. Cytotoxicity differences of gold (III) porphyrin 1a on
SUNE1 and NP 69 cells. Gold (III) porphyrin 1a had a greater
cytotoxic effect on the SUNE1 cancer cells than on cells of the
normal NP 69 cell line under the same condition.
cells. The numbers of apoptotic and non-apoptotic cells were
quantitated and presented as percentages (Fig. 3B). The
effects of gold (III) porphyrin 1a on cell death were further
investigated by flow cytometric analysis. The percentage of
apoptotic cells in SUNE1 cells after gold (III) porphyrin 1a
treatment was dramatically higher than in the control cells
(Fig. 4), and this result was in accordance with the DAPI
stain results. They also confirmed our previous findings (to
be published), that gold (III) porphyrin 1a induces apoptosis
in SUNE1 cells.
3.3 Proteome profiles of control and drug-treated
cancer cells
To further investigate the mechanism of cell apoptosis
induced by drugs, protein profiles of control, gold (III) por-
phyrin 1a- and cisplatin-treated SUNE1 cells were studied by
comparative proteomic analysis. Representative 2-D gel im-
ages for control, gold (III) porphyrin 1a- and cisplatin-treated
SUNE1 cells are shown in Fig. 5A. Figure 5B shows an
enlarged image overview for a typical master gel of a SUNE1
Figure 3. (A) Morphological changes induced by
gold (III) porphyrin 1a in SUNE1 and NP 69 cells.
The cells were stained by DAPI and visualized by
confocal microscope. Typical apoptotic morpho-
logical changes were detected in gold (III) por-
phyrin 1a-treated SUNE1 cells. (B) Percentage of
apoptotic and nonapoptotic cells under gold (III)
porphyrin 1a and cisplatin treatment in NP 69
and SUNE1 cells.
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Figure 5. (A) Representative 2-D gel images for control, gold (III) porphyrin 1a- and cisplatin-treated SUNE1 cells
(24-h incubation). (B) An image overview of a typical master gel from SUNE1 cells treated with gold (III) porphyrin
1a for 24h. Areas where significant and consistent alterations of protein expression were identified are circled.
cell treated with gold (III) porphyrin 1a for 24 h. Over 1000
protein spots were clearly separated on the gels. Circles
highlight major areas where significant and consistent
alterations of protein expression were identified. These
altered proteins were distributed evenly throughout the
entire gel, indicating that multiple clusters of proteins are
involved in the process of gold (III) porphyrin 1a-induced
apoptosis.
Table 1 shows protein ID obtained through PMF, to-
gether with proportionate differences of expression and
major functions of the identified altered proteins through
PMFmatching. These proteins can be classified into several
categories based on their major biological functions, includ-
ing cellular structural proteins, stress-related and chaperone
proteins, proteins involved in reactive oxygen species (ROS),
enzyme proteins and translation factors, proteins that me-
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Table 1. Protein alterations in SUNE1 cell under 1 mM gold (III) porphyrin 1a and 30 mM cisplatin treatments for 24h
Protein ID Change (fold) Major functions
Gold 1a Cisplatin
Stomatin-like 2 12.3 12.3 Cellular structure protein
Lamin C (fragment) 23.3 12.3 Cellular structure protein, nuclear envelope
Heat shock protein gp96 precursor (HSPgp96) 14.4 13.7 Stress-related, chaperone
Peroxiredoxin 1 12.9 12.5 Chaperone, and redox activities
Peroxiredoxin 6 12.1 12.5 Chaperone, and redox activities
Thioredoxin 12.8 13.8 Redox activities
Mitochondrial single-stranded DNA binding
protein (mtSSB)
undetected undetected Translation factor
Splicing factor 17 13.8 13.7 Translation factor
Protein disulfide isomerase 1 (PDI) 22.4 24.6 Translation factor, chaperone
Triosephosphate isomerase 1 (TPI 1) 21.1 12.4 Enzyme protein, glycolysis
Peptidylprolyl isomerase F, cyclophilin F (CypF) 23.1 23.0 Enzyme protein, catalysis
Oncoprotein 18 (Op18) 21.4 12.9 Cell proliferation or differentiation
Cyclophilin A (CypA) 22.0 11.7 Cell proliferation or differentiation
Calcyclin binding protein, Siah-interacting
protein (CacyBP)
21.4 22.4 Cell proliferation or differentiation
Rho GDP dissociation inhibitor alpha (GDI) 11.1 14.2 Cell proliferation or differentiation
Ras-related nuclear protein 11.6 12.5 Cell proliferation or differentiation
Porin isoform 1; voltage-dependent anion
channel 1 (VDAC1)
15.7 12.2 Cell proliferation or differentiation
Ionized calcium binding adapter molecule 2 (IBA 2) 13.2 15.1 Cell proliferation or differentiation
Chloride intracellular channel protein 1 (CLIC 1) 12.3 12.5 Cell proliferation or differentiation
Stratifin 15.9 14.4 Cell proliferation or differentiation, chaperone
Proteasome subunit, alpha type 3 21.1 15.2 Internal degradation
Proteasome subunit, beta type 4 21.3 14.6 Internal degradation
Proteasome subunit alpha type 6 11.6 12.6 Internal degradation
diate cell death and survival signaling, and proteins that
participate in the internal degradation system. Table 2
summarizes the parameters obtained in database match-
ing for protein identification, including NCBI database
access number, sequence coverage, and experimental
mass and pI.
3.4 Protein alterations in the cells treated with gold
(III) porphyrin 1a and cisplatin
Figure 6 illustrates the detailed comparison of proteins
involved in cellular structure and oxidative stress. In com-
parison with the control cells, stomatin-like 2 was signifi-
cantly up-regulated in both gold (III) porphyrin 1a- and cis-
platin-treated cells, while the nuclear envelope protein lamin
C was suppressed in cells treated with gold (III) porphyrin
1a. The up-regulation of stress-related chaperones and redox-
related proteins, including heat shock protein gp96 pre-
cursor (HSP gp96), peroxiredoxin 1 and 6, and thioredoxin
was also observed in the cells treated with both agents.
Figure 7 shows the altered expression of translation fac-
tors and enzyme proteins. Not all of the proteins in this
group were equally regulated. For example, triosephosphate
isomerase 1 (TPI1) was down-regulated by gold (III) por-
phyrin 1a treatment, but up-regulated by cisplatin treatment.
On the other hand, the negative regulation of PDI and
cyclophilin F was observed in the cells treated with both
agents. Mitochondrial single strand DNA binding protein
(mtSSB) was undetectable after treatment by both agents.
Figure 8 displays the signal transduction proteins altered
in the cells treated with gold (III) porphyrin 1a. The expres-
sions of Op18 and CypA were suppressed by gold (III) por-
phyrin 1a but elevated by cisplatin. Calcyclin binding protein
(CacyBP), GDI, and Ras-related nuclear protein were regu-
lated in the same manner by both agents. Three ion-related
signal transduction proteins, the voltage-dependent anion
channel 1 (VDAC1), ionized calcium binding adapter mole-
cule 2 (IBA 2), and chloride intracellular channel protein 1
(CLIC 1), were up-regulated under gold (III) porphyrin 1a
treatment. The over-expression of VDAC was much more
significant under treatment with gold (III) porphyrin 1a than
with cisplatin.
The differential expression of proteins involved in inter-
nal protein degradation is shown in Fig. 9. This group of
proteins, including proteasome subunit beta type 4, alpha
type 3, and alpha type 6, is up-regulated under cisplatin
treatment, but shows no significant change under gold (III)
porphyrin 1a treatment.
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Table 2. Results fromMALDI-TOF mass spectra and database searching for protein identification
Protein ID Accession
no. (NCBI)
Sequence
coverage
Experimental
mass (Da)/pI
Stomatin-like 2 704102 26.0% 38 534 / 6.9
Lamin C (fragment) 5031875 22.0% 65 135 / 6.4
Heat shock protein gp96 precursor (HSPgp96) 15010550 17.0% 90 195 / 4.7
Peroxiredoxin 1 4505591 39.0% 22 111 / 8.3
Peroxiredoxin 6 1718024 50.0% 25 035 / 6.0
Thioredoxin 135773 45.0% 11 738 / 4.8
Mitochondrial single-stranded DNA binding protein (mtSSB) 4507231 30.0% 17 260 / 9.6
Splicing factor 17 7706657 15.0% 65 522 / 6.6
Protein disulfide isomerase 1 (PDI) 7437388 26.0% 56 783 / 6.0
Triosephosphate isomerase 1 (TPI 1) 17389815 22.0% 26 642 / 6.4
Peptidylprolyl isomerase F, cyclophilin F (CypF) 5031987 22.0% 22 040 / 9.5
Oncoprotein 18 (Op18) 5031851 42.0% 17 303 / 5.8
Cyclophilin A (CypA) 1334908 34.0% 23 207 / 5.0
Calcyclin binding protein, Siah-interacting protein (CacyBP) 5454052 23.0% 27 774 / 4.7
Rho GDP dissociation inhibitor alpha (GDI) 1351015 22.0% 24 423 / 7.0
Ras-related nuclear protein 4507879 27.0% 30 723 / 8.6
Porin isoform 1; voltage-dependent anion channel 1 (VDAC1) 13899241 12.0% 17 068 / 6.6
Ionized calcium binding adapter molecule 2 (IBA 2) 14251209 26.0% 26 923 / 5.1
Chloride intracellular channel protein 1 (CLIC 1) 7656952 21.0% 26 210 / 8.3
Stratifin 5454052 23.0% 27 774 / 4.7
Proteasome subunit, alpha type 3 23110939 25.0% 27 648 / 5.2
Proteasome subunit, beta type 4 298507 21.0% 29 192 / 5.7
Proteasome subunit, alpha type 6 8394076 28.0% 27 400 / 6.3
Western blot analysis was used to confirm the altered
expressions of proteins in response to the treatment by these
drugs. Since a large number of altered proteins were identi-
fied and not all proteins can be confirmed by Western blot
analysis, we only selected PDI, GDI, stratifin, Op18, and
CypA, because their database matching scores are lower than
200 or they are differentially expressed after treatment by
gold (III) porphyrin 1a and cisplatin, respectively. Figure 10
shows the Western blot results of GDI, Op 18, Cyp A, strati-
fin, and PDI. The altered expression ratio of these proteins
matched well with the ratio detected in 2-DE.
4 Discussion
4.1 Tumor targeting therapeutic agents
It has been reported in previous studies that porphyrins can
be rapidly and preferentially taken up by cancer cells [30, 31].
Rapidly proliferating cells, such as cancer cells, provide
opportunities for the porphyrins to interact with G quad-
ruplexes on single-stranded (ss) DNA [32]. This tumor selec-
tivity of porphyrin and its derivatives, together with their
photodynamic action, has eventually enabled these por-
phyrin compounds to be used in clinical applications as
sensors for photodynamic therapy for various cancers [33,
34]. As gold (III) porphyrin 1a exhibits a higher cytotoxicity
towards tumor (SUNE1) cells than towards normal cells (NP
69), it is reasonable to expect that this porphyrin containing
agent may also exhibit tumor selectivity in vivo.
4.2 Mitochondria-mediated apoptotic pathway
Apoptosis is a process of gene-mediated programmed cell
death essential for the elimination of unwanted cells in var-
ious biological systems. One of the two major apoptotic
pathways is the mitochondria-mediated pathway. Mitochon-
dria play a crucial role in apoptosis by releasing several
apoptogenic molecules, including cytochrome c and Smac/
Diablo. They are released from the intermembrane space of
mitochondria into the cytoplasm in response to a variety of
death-promoting stimuli [35–37]. The release of cytochrome
c from mitochondria is mediated by VDAC1. VDAC1 is a
mitochondrial outer membrane channel protein, which
functions as the pathway for the movement of various sub-
stances in and out of the mitochondria [38]. It is considered
to be a component of the permeability transition pore oligo-
protein complex that plays a role in the permeability transi-
tion [39, 40]. VDAC1 also plays an essential role in Bax/Bak-
induced apoptotic mitochondrial changes in the process of
apoptosis in mammalian cells [41–43]. In this process, the
pro-apoptotic proteins Bax and Bak bind to VDAC1, and
enhance its permeability so that cytochrome c passes
through the channel and releases to cytoplasm [41–43]. Our
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Figure 6. Detailed alteration patterns of cellular structure protein,
chaperone proteins and proteins related to oxidative stress,
including stomatin-like 2, lamin C, heat shock protein gp96
(HSPgp96), Prx 1 and 6, and thioredoxin.
data on VDAC1 up-regulation (Fig. 8) and Bax over-expres-
sion (to be published) suggest that gold (III) porphyrin 1a
may induce cell death via the mitochondria-mediated apop-
tosis pathway.
Interestingly, we found that the related protein mtSSB
was suppressed in SUNE1 cells treated with gold (III) por-
phyrin 1a (Fig. 7). mtSSB is a conserved molecule that binds
to ssDNA, the template for the synthesis of lagging DNA
strand synthesis mitochondrial DNA (mtDNA) replication,
and prevention of mtDNA renaturation [44, 45]. The down-
regulation of mtSSB expression by gold (III) porphyrin 1a
may destabilize mtDNA during replication, and further lead
to apoptosis. These data again confirm that gold (III) por-
phyrin 1a may induce mitochondria-mediated apoptosis.
Similarly, studies have demonstrated that cisplatin triggers
apoptosis through the mitochondrial pathway in several
cancer cell lines [46, 47]. Both gold (III) porphyrin 1a and
cisplatin altered the expression of VDAC1 and mtSSB, sug-
gesting that they may share the same mitochondrial apopto-
tic pathway.
Figure 7. Detailed alterations of translation factors and enzyme
proteins, including mtSSB, splicing factor 17, PDI, triosephos-
phate isomerase 1 (TPI1), and cyclophilin F (CypF).
4.3 Induction of ROS-related proteins
Gold (III) porphyrin 1a induced alterations of the proteins
involved in defending oxidative stress by up-regulating the
expressions of thioredoxin, peroxiredoxin 1, and peroxi-
redoxin 6 (Fig. 6). Alterations in cellular oxidative status have
been shown to play an important role in inducing apoptotic
cell death [36, 48, 49]. Low levels of ROS are required in the
regulation of a broad range of normal cellular responses,
including proliferation and cell survival [50–52]. Oxidative
modifications of redox-sensitive transcription factors such as
AP-1, transcription factor NF-kB, HIF-1a, and intermediate
signaling molecules such as protein kinase C, ERK, and JNK,
participate in this type of process [50, 53]. On the other hand,
high levels of ROS induce a state of oxidative stress in cells,
which may damage cellular DNA, proteins, and lipids, and
result in cell-cycle arrest, cellular senescence, and cell death
[50]. The degree of oxidative stress and final cell fate are de-
pendent on the balance between ROS anabolism and catab-
olism together with other factors. Cells are equipped with
multiple antioxidant defense mechanisms for survival [54].
Among them, two important defense mechanisms were a
thiol reducing buffer consisting of small proteins with
redoxactive sulfhydryl moieties like glutathione (GSH) and
thioredoxin; and enzymatic systems including superoxide
dismutase, catalase, and glutathione peroxidase [55].
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Figure 8. Detailed alteration patterns of proteins participating in
cell proliferation or differentiation. This group of proteins con-
tains Op18, CypA, CacyBP, GDI, Ras-related nuclear protein,
VDAC1, IBA 2, CLIC 1, and stratinfin.
Figure 9. Detailed alteration patterns of proteins involved in the
internal degradation system, including proteasome subunit
alpha type 3 and type 6, and beta type 4.
Thioredoxin is a multifunctional and ubiquitous protein
characterized by having a redox-active disulfide/dithiol
within the conserved active site sequence: -Trp-Cys-Gly-Pro-
Cys-Lys- [56]. Previous studies have revealed that thioredoxin
exerts a protective effect on cells exposed to cisplatin, and its
over-expression is implicated in the mechanism of cisplatin
resistance [57]. Our results (Fig. 7) also showed that thio-
redoxin was highly up-regulated in cells treated by cisplatin-
and in gold (III) porphyrin 1a-treated cells, which suggests
that gold (III) porphyrin 1a may induce oxidative stress in
cancer cells.
Peroxiredoxins (Prx) are a group of recently characterized
thiol-containing proteins with efficient antioxidant capacity,
capable of antagonizing hydrogen peroxide in living cells. It
has been reported that Prx enzymes catalyze the reduction of
hydrogen peroxide to water and alkyl hydroperoxides to the
corresponding alcohols [58]. The Prx also influence a variety
of cellular processes that are sensitive to ROS and play a role
in signal transduction and gene expression related to altera-
tions in cellular ROS levels [59]. Increased Prx expression
correlated with chemoresistance by cisplatin treatment [60,
61]. Our results further suggest that gold (III) porphyrin 1a
may induce ROS, which may subsequently alter mitochon-
drial membrane potential and ultimately induce mitochon-
dria-mediated apoptosis. Similar findings have been report-
ed in respect of cisplatin-induced apoptosis in various cancer
cell lines [46, 47].
PDI was down-regulated in SUNE1 cells treated with
both gold (III) porphyrin 1a and cisplatin (Fig. 7). PDI is a
multifunctional protein mainly located in the endoplasmic
reticulum (ER). During protein folding in the ER, PDI cata-
lyzes thiol/disulfide exchange, including disulfide bond for-
mation and rearrangement reactions [62]. The thiol/disulfide
centers of the two thioredoxin-like domains function as two
independent active sites. These two sites could lead to
increased PDI expression in neurons, and result in both
attenuation of the loss of cell viability in vitro and reduction
of the number of DNA-fragmented cells in the rat hippo-
campal CA1 sub region in vivo [62]. Recently, Nomura and
colleagues [63, 64] reported that up-regulated PDI may exert
a protective effect against apoptotic cell death. The observed
down-regulated expression of PDI in our study indicates that
gold (III) porphyrin 1a triggers cancer cells towards apopto-
sis instead of proliferation.
4.4 Altered proteins associated with cell proliferation
or differentiation
CacyBP, a novel protein target of calcyclin involved in cal-
cium signaling pathways in neuronal tissue, was up-regu-
lated in proliferating and differentiating cells [65]. Down-
regulation of CacyBP expression by gold (III) porphyrin 1a
treatment (Fig. 8) suggests that gold (III) porphyrin 1a may
induce cell apoptosis through affecting the processes of cell
proliferation and differentiation.
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Figure 10. Western blot analysis of the altered proteins in gold (III) porphyrin 1a-treated SUNE1 cells. The altered
expression ratio of GDI, Op18, Cyp A, stratifin and PDI was normalized to the intensity of b-actin, and presented as
a chart.
CLIC 1 is a transmembrane protein that forms an
essential component of an ion channel complex. Expression
of CLIC 1 in cultured cells has been reported to lead to
increased chloride channel activity in plasma and nuclear
membranes [66, 67]. Besides its novel role as a typical inte-
gral membrane protein, studies have also demonstrated that
chloride ion (Cl–) conductance changes in synchrony with
the cell cycle in a number of different cells [68]. Expression of
a Cl2 current was markedly up-regulated after cell cycle
arrest, with the highest Cl2 channel activity in early G1 and
the lowest activity in G0/G1 and S phase [69, 70]. The
observed up-regulation of CLIC 1 in this study (Fig. 8) is
consistent with our previous data showing that gold (III)
porphyrin 1a abrogated SUNE1 cell cycle at G1 and inhibited
DNA synthesis (to be published).
4.5 Alteration of proteins involved in the internal
protein degradation system
The proteins associated with internal protein degradation
system, including proteasome subunit alpha type 3 and 6,
and beta type 4, are up-regulated by cisplatin, and do not alter
significantly by gold (III) porphyrin 1a (Fig. 9). Proteasome
is a multisubunit enzyme complex that was initially thought
to be a mere recycler of damaged or misfolded proteins.
However, this enzyme complex has recently been found to
play a central role in the regulation of proteins that control
cell cycle progression and apoptosis [71]. Inhibition of pro-
teasome can stabilize various cell cycle-regulatory proteins,
including cyclin-dependent kinase inhibitors (CDKI) (e.g.,
p21 and p27), tumor suppressors (e.g., p53), and the tran-
scription factor NF-kB [72–75]. Interference of proteasome
function in a proliferating cell can therefore set cell arrest at
the G0/G1 or G2 phase, leaving the cell with three alter-
natives: to remain in the G0/G1 or G2 phase, to follow a dif-
ferentiation pathway, or to undergo apoptosis [76]. The up-
regulation of the proteasome has also been shown to be one
of the key factors leading to drug resistance in chemotherapy
[77].
4.6 Concluding remarks
Based on our findings in this study, we conclude that treat-
ment with gold (III) porphyrin 1a caused multiple effects
leading to apoptosis in SUNE1 cells. The balance between
pro-apoptotic and anti-apoptotic signals determines the final
fate of cancer cell survival. The general differences between
the expressed proteomes implies that gold (III) porphyrin 1a
may exert its cytotoxicity on cisplatin-resistant cancer cell
lines. There is therefore a good chance that gold (III) por-
phyrin 1a could be successfully used in the treatment of cis-
platin-resistant patients. Clearly, this study is only the
beginning of a series of investigations, and further func-
tional studies are needed to understand the overall action
mechanisms of gold (III) porphyrin 1a.
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